Recurrence of Uveitis after Discontinuation of Infliximab
Recurrence of Uveitis after Discontinuation of Infliximab
复制标题
DOI：
10.3109/09273948.2013.812222
复制
发表时间：
2014-04-01
影响因子：
3.3
通讯作者：
Acharya, Nisha R.
中科院分区：
文献类型：
--
作者：
Shakoor, Akbar;Esterberg, Elizabeth;Acharya, Nisha R.
目的：评价炎症得到控制后停用英夫利昔单抗后葡萄膜炎的复发。方法：对1998年至2010年在普罗科特基金会就诊的患者进行了一项回顾性队列研究，这些患者在通过标准化葡萄膜炎命名标准实现糖皮质激素节省控制后停用英夫利昔单抗。主要结果是葡萄膜炎复发患者的比例。结果：18名患者在炎症控制后试图停用英夫利昔单抗，11名患者复发。中位复发时间为603天(95%可信区间：85-1461天)。幼年特发性关节炎相关性葡萄膜炎患者(n=4)的复发时间(中位复发时间：76天，p=0.002)比非青少年特发性关节炎相关性葡萄膜炎患者(中位数为1,169天)快。结论：大多数接受英夫利昔单抗控制炎症的患者在停止治疗后复发。与其他患者相比，JIA患者的复发更快。
Purpose: To evaluate the recurrence of uveitis after discontinuation of infliximab once control of inflammation is achieved.Methods: A retrospective cohort study was conducted of patients seen at the Proctor Foundation between 1998 and 2010 who discontinued infliximab after achieving corticosteroid-sparing control by Standardization of Uveitis Nomenclature criteria. The main outcome was the proportion of patients who had a relapse of uveitis.Results: Eighteen patients attempted to discontinue infliximab after achieving control of inflammation, and 11 patients had a relapse. Median time to relapse was 603 days (95% CI: 85-1461 days). Patients with juvenile idiopathic arthritis (JIA)-associated uveitis (n = 4) relapsed faster (median time to relapse: 76 days, p = 0.002) compared with patients who did not have JIA-associated uveitis (median = 1169 days).Conclusions: The majority of patients who achieved control of inflammation on infliximab had a recurrence after discontinuing therapy. Patients with JIA experienced recurrence faster compared to other patients.